- The product developed by Pfizer and BioNTech is 90% effective, the producer says. The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020.
- Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued.
- After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the Data Monitoring Committee performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at seven days after the second dose.
- Pfizer says there are no serious side effects. If key indicators are safe, the world may have a tool to tackle the pandemic in a week.
- The European Commission has already agreed to sign an agreement with the developers on the purchase of 300 million doses of the coronavirus vaccine.
Zelensky asks Merkel to assist in allocating COVID-19 vaccine to Ukraine
The parties agreed to further coordinate efforts to overcome the consequences of the pandemic.
President of Ukraine Volodymyr Zelensky on November 10 had a phone call with Germany's Chancellor Angela Merkel during which he asked the German leader to assist in supplying a U.S.-German-developed COVID-19 vaccine to Ukraine.
"We welcome the breakthrough achieved by the German company BioNTech together with the American company Pfizer in the development of a coronavirus vaccine. This is very encouraging news. I would like to ask for your assistance in taking into account the interests of Ukraine when planning the supply of COVID-19 vaccine," Zelensky said, according to the press service of the Ukrainian President's Office.
Pfizer vaccine


The End of the Minsk Group: A New Diplomatic Map of the Caucasus
04.Sep.2025
Turkish Defense Industry Raises Concerns in Greece
03.Sep.2025
A Referendum in Armenia Could Be Held No Earlier Than June 2027. Expert Analysis by Ruben Megrabyan
02.Sep.2025
Ukrainian Forces Liberate Udachne in Donetsk Region
02.Sep.2025
Ursula von der Leyen’s Plane Makes Emergency Landing in Bulgaria: Suspected Russian GPS Jamming
02.Sep.2025
Putin Arrives in China for SCO Summit: New Escalation of the War in Ukraine Amid Negotiations
31.Aug.2025
Modi and Zelensky Discuss Peaceful Settlement: India Hopes to Raise the Ukraine Issue at the SCO Summit
31.Aug.2025
Iran and Armenia Strengthen Strategic Partnership: Focus on the “North–South” Transport Corridor
30.Aug.2025
Putin and Erdoghan to Discuss the Situation in the South Caucasus at the SCO Summit in Tianjin
28.Aug.2025
Public Opinion in Moldova: EU Supported, Unification with Romania Rejected
26.Aug.2025